Still Ineffective When Added to Trikafta, Sionna Ends Development of Cystic Fibrosis Drug Candidate
SION-719 failed to further reduce sweat chloride, dealing a clinical setback to the concept of directly stabilizing the NBD1 structure of the CFTR protein; the company will discontinue this add-on treatment path and reassess its allocation of capital.